The Latest Breaking News from GoodRx

Baird has decided to maintain its Neutral rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $7.00 to $6.00. Shares of GoodRx Holdings are trading up 6.94% over the last 24 hours, at $6.32 per share. A move to $6.00 would account for a 5.06% decline from the…

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023.  TXMD will also enter into a long-term services agreement to…

Consumer-focused digital healthcare, GoodRx Holdings Inc (NASDAQ: GDRX) shares are plunging after the company's 

GoodRx Holdings Inc (NASDAQ: GDRX) is plunging Tuesday after the company reported worse-than-expected fourth-quarter financial results and issued guidance below estimates.